ArticleJournal of gastrointestinal oncology2026
Diagnostic biopsy-to-treatment interval and risk of recurrence in localized pancreatic ductal adenocarcinoma: every week counts.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The impact of the interval between diagnostic biopsy and treatment initiation on oncologic outcomes in localized pancreatic ductal adenocarcinoma (PDAC) remains poorly characterized. We conducted an institutional review board (IRB)-approved retrospective cohort study of 91 consecutive patients diagnosed with localized PDAC between 2016 and 2024 at a tertiary care academic medical center. The primary exposure was the interval (days) from diagnostic biopsy to initiation of any curative-intent treatment. The primary outcome was time from treatment initiation to develop recurrence or distant metastasis. Kaplan-Meier analysis and Cox proportional hazards (PH) regression were used to assess associations. Models were adjusted for age, sex, radiation therapy, and surgery, and the PH assumption was verified using scaled Schoenfeld residual tests. Of 91 patients (39 male, 52 female), 61 (67%) developed recurrence or distant metastasis during follow-up. The median time to recurrence or metastasis was 21.7 months [95% confidence interval (CI): 17.9-24.9]. The median biopsy-to-treatment interval was 27 days [interquartile range (IQR): 21-38] among patients without recurrence or distant metastasis and 29 days (IQR: 24-44) among those with the event. Each additional 7-day delay from biopsy to treatment initiation was associated with a 9% increase in the hazard of recurrence or metastasis on multivariable analysis [adjusted hazard ratio (aHR), 1.09; 95% CI: 1.02-1.16; P=0.01]. Absence of surgery was also independently associated with worse outcomes (aHR, 2.54; 95% CI: 1.12-5.76; P=0.03). In this single-institution retrospective cohort, a longer biopsy-to-treatment interval was associated with an increased hazard of recurrence and distant metastasis. These findings should be interpreted cautiously given the retrospective single-center design, limited sample size, and absence of key prognostic covariates including resectability status; validation in larger prospective multi-institutional cohorts is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.